-
-
Over the years, different tocolytics have been in vogue, only to be discarded later because meta-analyses showed that the agent simply did not work. This month's review will focus on nifedipine, a medication that has been in and out of favor for more than 20 years.
-
This publication is an update on osteoporosis screening from the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation.
-
Although the annual incidence of all gynecological malignancies remains between 75,000 and 80,000, a far greater number of women with this history are survivors.
-
In this issue: Calcium supplements and MI; birth control pills and VTE; ACE inhibitors and breast cancer risk; spending on pharmaceuticals; and FDA actions.
-
When HIV is not diagnosed until women go into labor, their infants usually are treated soon after birth with the antiretroviral drug zidovudine to prevent infant infection.
-
Amphora, under development by Evofem of San Diego, is a bioadhesive acid-buffering gel that coats the vaginal wall and cervix. Amphora helps maintain a woman's natural pH level between 3.8 and 4.2.
-
Trichomoniasis is the most common curable sexually transmitted infection (STI) in young, sexually active women, according to the Centers for Disease Control and Prevention. An estimated 7.4 million new cases occur each year in U.S. women and men.
-
Four hundred thousand (1.6% of U.S. adolescents) experience serious physical and/or sexual dating violence each year.
-
Since results of the 2002 Women's Health Initiative (WHI) report suggested that use of menopausal hormone therapy increases risk of coronary heart disease, science has examined the timing of therapy initiation on safe use of such treatment.
